枳术宽中胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎的疗效观察

目的探讨枳术宽中胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎的临床疗效。方法选取2014年9月—2015年9月在郫县人民医院接受治疗的反流性食管炎患者106例,按照治疗方法的差别分成对照组和治疗组,每组各53例。对照组患者口服枸橼酸莫沙必利片,5 mg/次,3次/d;同时口服兰索拉唑肠溶片,20 mg/次,2次/d;治疗组在对照组基础上口服枳术宽中胶囊,3粒/次,3次/d。两组患者均治疗8周。观察两组的临床疗效,比较两组患者的临床症状和生活质量情况。结果治疗后,对照组和治疗组的总有效率分别为81.13%、94.34%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者烧心、反酸、胸骨后疼痛评分均显著下降,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的降低程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者的生理功能、生理职能、身体疼痛、总体健康、生命活力、社会职能、情感职能及精神健康评分均显著升高,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的升高程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论枳术宽中胶囊联合兰索拉唑和莫沙必利治疗反流性食管炎具有较好的临床疗效,能明显改善患者的临床症状,提高患者的生活质量,具有一定的临床推广应用价值。

Clinical observation of Zhizhu Kuanzhong Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis

Objective To investigate the clinical effect of Zhizhu Kuanzhong Capsules combined with lansoprazole and mosapride in treatment of reflux esophagitis. Methods Patients (106 cases) with reflux esophagitis in Pixian People''s Hospital from September 2014 to September 2015 were enrolled in this study. According to the difference treatment plan, patients were randomly divided into the control and treatment groups, and each group had 53 cases. Patients in the control group were po administered with Mosapride Citrate Tablets, 5 mg/time, three times daily. And patients in the control group were also po administered with Lansoprazole Enteric-coated Tablets, 20 mg/time, twice daily. Patients in the treatment group were po administered with Zhizhu Kuanzhong Capsules on the basis of the control group, 3 grains/time, three times daily. After treatment, the clinical efficacies were evaluated, and clinical symptom and quality of life in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.13% and 94.34%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of heartburn, acid regurgitation, and retrosternal pain in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the scores of physiological function, physiological role, body ache, general health, life vigor, social function, emotional role, and mental health in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Zhizhu Kuanzhong Capsules combined with lansoprazole and mosapride has clinical curative effect in treatment of reflux esophagitis, and can improve clinical symptoms, enhance quality of life, which has a certain clinical application value.